Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

作者：Xiaoshuang Kong, Xudong Zhang, Mengjie Ding, Xiaoyan Feng, Meng Dong, Lei Zhang, Xiaorui Fu, Ling Li, Xin Li, Zhenchang Sun, Jiaqin Yan, Xinhua Wang, Xiaolong Wu, Qingjiang Chen, Mingzhi Zhang, Linan Zhu · 发表于：Cancer Medicine · 年份：2023 · DOI：10.1002/cam4.5615 · 被引用次数：10 · 研究领域：Lymphoma Diagnosis and Treatment、CNS Lymphoma Diagnosis and Treatment、Cutaneous lymphoproliferative disorders research

BACKGROUND: There is an urgent need for effective treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (R/R-DLBCL). This trial investigated the efficacy of decitabine in combination with rituximab, cisplatin, cytarabine, dexamethasone (RDHAP) in R/R-DLBCL. METHODS: 56 patients were divided into two groups (decitabine-RDHAP group. n = 35; RDHAP group, n = 21). The primary endpoints were the overall response rate (ORR) and duration of remission (DOR). Secondary objectives were toxicity, progression-free survival (PFS), and overall survival (OS). RESULTS: The ORR was 40% and 33% for decitabine-RDHAP and RDHAP groups, respectively, with no difference between the groups. The DOR for the decitabine-RDHAP regimen was higher than that for the RDHAP regimen (p = 0.044). After a median follow-up of 12.0 months, the median PFS and OS were 7.0 and 17.0 months for in the decitabine-RDHAP group and 5.0 and 9.0 months in the RDHAP group with no significant differences between the two groups (p = 0.47, 0.17). The incidence of adverse events was not significantly different between groups. CONCLUSION: The decitabine-RDHAP regimen is effective and well tolerated, and is a promising salvage regimen for R/R-DLBCL.